Investigation of Possible Changes in Serum Adiponectin Adipsin and Visfatin Levels in Diabetic Rats
Abstract views: 2
/ 
PDF downloads: 0
DOI:
https://doi.org/10.5281/zenodo.17099818Keywords:
Rat, Diabetes, Adiponectin, Adipsin, VisfatinAbstract
Objective: Diabetes Mellitus is a health problem with a high treatment cost. It has been suggested that some of the adipokines worsen diabetes, while others have antidiabetic effects and reduce diabetic complications. However, it seems that the possible relationships between adipokines and diabetes are not sufficiently clarified. For this reason, in our experimental research project; Serum levels of adipokines and the effects of possible changes on glucose metabolism in diabetic rats will be investigated.
Materials and Methods: Twenty-one Wistar albino male rats weighing between 380-434 g were provided for the experimental study. During the experiment, these rats' room temperatures, nutrition and living environments were adjusted according to the groups. 21 adult male rats were divided into 3 groups, 7 in each. Adiponectin, visfatin and adipsin levels of the groups were recorded by taking their blood serum. In addition, the levels of Glucose 6 phosphate dehydrogenase, Pyruvate kinase and Hexokinase, which are liver enzymes of rats, were evaluated.
Results: The body weights of the diabetic group rats were found to be very low and statistically significant in the post-procedure measurements (p<0.001). In addition, blood glucose values were found to be significantly higher and statistically significant in both diabetic and metformin group rats compared to pre-procedure (p<0.001). Adiponectin and adipsin levels in the diabetic group were found to be lower and statistically significant compared to both the control and metformin groups (p<0.05). In addition, visfatin level was found to be higher and statistically significant in the diabetic group compared to the control group (p<0.05).
Conclusion: While glucose levels and visfatin values were higher in diabetic rats compared to control and metformin groups, we found low adiponectin, adipsin and insulin resistance values.
References
Özdoğan E. Tip 2 diyabet hastalarında kan lipid düzeylerinin HbA1c ve obezite ile ilişkisi [specialization thesis]. İstanbul: İstanbul Eğitim ve Araştırma Hastanesi Aile Hekimliği Koordinatörlüğü; 2007.
Atalay M, Laaksonen DE. Diabetes, oxidative stress and physical exercise. J Sports Sci Med. 2002;1(1):1.
Viswanathan V, Madhavan S, Rajasekar S, et al. Amputation prevention initiative in South India. Diabetes Care. 2005;28(4):1019-1020.
Can ÖD. Deneysel diyabetin neden olduğu metabolik ve davranışsal değişimler üzerine insülinin ve Hypericum perforatum L. ekstresinin etkileri [doctoral thesis]. Eskişehir: Anadolu Üniversitesi Sağlık Bilimleri Enstitüsü; 2007.
Gujral UP, et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281(1):51-63.
Phillips C. Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. Nutrients. 2013;5(1):32-57.
Nanri A. Nutritional epidemiology of type 2 diabetes and depressive symptoms. J Epidemiol. 2013;23(4):243-250.
DiSpirito JR, Mathis D. Immunological contributions to adipose tissue homeostasis. Semin Immunol. 2015;27(5):427-432.
Sun K, Park J, Gupta OT, et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 2014;5:3485.
Kloting N, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506-E515.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-430.
Nedvídková J, Smitka K, Kopský V, Hainer V. Adiponectin: an adipocyte-derived protein. Physiol Res. 2005;54(2):133-140.
Van Harmelen V, Reynisdottir S, Cianflone K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation stimulating protein and insulin. J Biol Chem. 1999;274(26):18243-18251.
Maslowska M, Vu H, Phelis S, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest. 1999;29(8):679-686.
Thundyil J, et al. Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012;165(2):313-327.
Spranger J, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226-228.
Zimmet PZ, Alberti KGMM. Epidemiology of diabetes: status of a pandemic and issues around metabolic surgery. Diabetes Care. 2016;39(6):878-883.
World Health Organization Study Group. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
Gürlek A. İnsülin direncinde genetik faktörler. In: Klinik Endokrinoloji. İzmir: Meta Basım; 2001:49-53.
Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64(6):1169-1173.
Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
Hotta K, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50(5):1126-1133.
Panidis D, et al. Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of D4-androstenedione. Hum Reprod. 2004;19(8):1728-1733.
Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005;83(6):1708-1716.
Gu HF, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes. 2004;53(Suppl 1):31-35.
Filippatos TD, et al. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol. 2010;8(1):12-28.
Doğru T, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-29.
Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405-408.
Lo JC, Ljubicic S, Leibiger B, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41-53.
Luzzatto L, Poggi V. Glucose-6-phosphate deficiency. In: Orkin SH, Nathan D, Ginsburg D, et al, eds. Hematology of Infancy and Childhood. 7th ed. Philadelphia: WB Saunders Company; 2009:883-907.
Kruszynska YT, Mulford MI, Baloga J, et al. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetologia. 1998;47(7):1107-1113.
Özışık M. Bazal/bolus insülin tedavisine geçilen tip 2 diyabetlilerde insan insülinleri (regüler/NPH) ile insülin analoglarının (lispro/glargin) etkinliğinin karşılaştırılması [specialization thesis]. İstanbul: Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi; 2005.
Heinrichs M, Jacobasch G, Scheiner-Bobis K, et al. Human erythrocyte pyruvate kinase (L/R-PK): production and characterization of a monoclonal antibody. Biomed Biochim Acta. 1987;46(3):223-228.
Yılmaz S, Üstündağ B. Streptozotosin ile diyabet oluşturulan ratların karaciğer ve böbrek dokularında pirüvat kinaz aktivite düzeyleri. Turk J Vet Anim Sci. 2002;26(3):549-553.
Saxena AK, Srivastava P, Baquer NZ. Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and -independent tissues of diabetic rats. Eur J Pharmacol. 1992;216(1):123-126.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 IKSAD JOURNAL
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 